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Background: Activation of the type I interferon (IFN) pathway has been implicated in the
pathogenesis of systemic autoimmune disorders but its role in the pathogenesis of organ-
specific autoimmunity is limited. We tested the hypothesis that endogenous expression
of type I IFN functional activity contributes to the pathogenesis of autoimmune thyroid
disease (ATD) and type I diabetes (T1DM).
Methods: We studied 39 patients with ATD and 39 age and sex matched controls along
with 88T1DM patients and 46 healthy matched controls respectively. Available clinical and
serological parameters were recorded by chart review, and thyroid ultrasound was per-
formed in 17 ATD patients. Type I IFN serum activity was determined in all subjects using
a reporter cell assay. The rs1990760 SNP of the interferon-induced helicase 1 gene was
genotyped in ATD patients.
Results: Serum type I IFN activity was increased in patients with ATD and T1DM com-
pared to controls (p-values: 0.002 and 0.04, respectively). ATD patients with high type I IFN
serum activity had increased prevalence of antibodies against thyroglobulin (anti-Tg) and
cardiopulmonary manifestations compared to those with low IFN activity. Additionally, the
presence of micronodules on thyroid ultrasound was associated with higher type I IFN lev-
els. In patients withT1DM, high IFN levels were associated with increased apolipoprotein-B
levels.
Conclusion: Serum type I IFN activity is increased in ATD and T1DM and is associated
with specific clinical, serological, and imaging features. These findings may implicate type
I IFN pathway in the pathogenesis of specific features of organ-specific autoimmunity.
Keywords: type I interferon, autoimmune thyroid disease, organ-specific autoimmunity, type I diabetes
INTRODUCTION
Autoimmune thyroid diseases (ATD), including Hashimoto’s thy-
roiditis (HT) and Graves’ disease (GD), as well as type I Diabetes
Mellitus (T1DM) are prototype organ-specific autoimmune dis-
orders characterized by loss of immunological tolerance against
thyroid and β-cell pancreatic antigens, lymphocytic infiltration of
the thyroid gland and the insulin producing pancreatic islands,
and various degrees of organ dysfunction (1, 2).
Autoimmune thyroid disease and T1DM share common fea-
tures with systemic autoimmune disorders, such as multifacto-
rial etiology involving both genetic and environmental factors,
female predominance (ATD), and familial aggregation associ-
ated with other organ-specific or systemic autoimmune disor-
ders (3–5). Despite the fact that ATD is classically considered
as a disease that predominantly affects the thyroid gland, non-
specific systemic features such as musculoskeletal complaints, sicca
symptomatology, pregnancy loss, and various neurological man-
ifestations may also occur (6). Taken together, these observations
suggest that clinically different autoimmune phenotypes might
share common pathogenetic pathways.
While increasing evidence over the last few years suggests a
dominant role for the type I interferon (IFN) pathway in the patho-
genesis of many systemic autoimmune disorders such as systemic
lupus erythematosus (SLE) and Sjogren’s syndrome (7, 8), limited
data are available regarding the role of the IFN-α pathway in the
pathogenesis of organ-specific autoimmune disorders (5). Recent
studies have suggested that the Ala946Thr polymorphism of the
interferon-induced helicase 1 gene (IFIH1) (SNP ID rs1990760)
is associated with type I diabetes (T1DM), GD, and Addison’s dis-
ease (9, 10). Recent data also support the protective role of rarer
IFIH1 alleles against T1DM (10). The IFIH1 gene, also known
as the melanoma differentiation-associated 5 (MDA-5), encodes
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a putative RNA helicase implicated in sensing of viral RNA and
generation of antiviral responses (11). In SLE, risk alleles of the
IRF5, IRF7, and IFIH1 genes have been associated with high type
I IFN levels and distinct autoantibody profiles (12, 13).
Given that development of thyroid autoimmunity and to a
lesser extent T1DM, either separately or in combination, has been
previously described after IFN-α treatment (14–18), we hypothe-
sized that activation of the type I IFN pathway may contribute to
the pathogenesis of these organ-specific autoimmune disorders.
To test this hypothesis, type I IFN activity was measured in sera
of patients with ATD, T1DM, and healthy controls (HC), using a
sensitive functional assay, and its presence was related to various
clinical, biochemical, morphological, and genetic indices.
PATIENTS AND METHODS
STUDY PARTICIPANTS
Thirty-nine patients with ATD (13 with GD and 26 with HT)
and 39 age and sex matched HC without evidence of under-
lying autoimmune disease along with 88 patients with T1DM
and 46 HC matched for sex and age were studied. Study par-
ticipants were followed in the Department of Pathophysiology,
University of Athens (ATD patients), and the General Pediatric
Hospital Ag.Sophia (TIDM patients) (19). Study subjects signed
an informed consent form prior to enrollment in the study.
All patients underwent a complete medical history and physi-
cal examination. Baseline hematological and biochemical profiles
were performed and detailed medical therapy was recorded in all
patients.
All ATD participants completed a specific questionnaire
addressing symptoms/signs related to systemic autoimmune dis-
eases. Symptoms/signs and parameters recorded included skin
manifestations, musculoskeletal features, Raynaud’s phenomenon,
sicca symptoms, renal involvement, hematological manifestations
(autoimmune hemolytic anemia, leucopenia, thrombocytopenia)
cardiovascular and/or pulmonary features (pulmonary hyperten-
sion, pulmonary fibrosis, pleuritis, pericarditis, coronary artery
disease), and neurological complications (headaches, stroke, white
matter microangiopathy, transverse myelitis, cranial/peripheral
neuropathy). The presence or absence of autoantibodies to thy-
roid antigens, including antibodies to thyroglobulin (anti-Tg)
and thyroid peroxidase (anti-TPO), thyroid stimulating hormone
receptor (TSHR), as well as thyroid stimulating hormone (TSH)
levels at the time of diagnosis were also recorded. The normal
range of TSH values was 0.5–5 (mU/L). On this basis, TSH levels
were defined as high and low (>5 and <0.5 mU/L, respectively).
Patients with T1DM were suffering from no other disease
and/or DM related complications and were not taking any med-
ications other than insulin. Biochemical parameters that were
particularly recorded in patients with T1DM included cholesterol,
triglycerides, HbA1c, apolipoprotein-A and -B as well C-reactive
protein (CRP) levels.
Serum from ATD and T1DM patients and controls was col-
lected and stored at −80°C until assayed. Informed consent was
obtained from ATD patients and controls as well as from the
parents of both diabetic and healthy subjects, according to the
Declaration of Helsinki. The study has been approved by the Ethics
Committee of Athens University Medical School.
SERUM TYPE I IFN ACTIVITY
Type I IFN activity was measured in sera derived from ATD,
T1DM, and HC using a reporter cell assay, which measures the
ability of serum to upregulate IFN-inducible genes in an IFN sen-
sitive cell line as previously described (20). In brief, cells of the
WISH epithelial cell line (ATCC) express the type I IFN receptor
and are highly responsive to type I IFN. WISH cells were plated
at a density of cells/mL in 96 well plates in Minimal Essential
Media (Cellgro, Herndon, VA, USA) with 10% fetal calf serum
(FCS). The cells were then cultured with 50% patient serum for
6 h. Recombinant human IFN-α (IFNaA; BioSource International,
Camarillo, CA, USA) and media were used as positive and negative
controls respectively. Subsequently, total cellular mRNA was puri-
fied from stimulated cells at the end of the culture period using
the Qiagen TurboCapture oligo-dT coated 96 well plate system as
per manufacturer protocol (Qiagen, Valencia, CA, USA) and was
reverse-transcribed to cDNA immediately following purification
using the Superscript III reverse transcriptase system from Invitro-
gen (Carlsbad, CA, USA). Quantitative real-time polymerase chain
reaction (PCR) was then used to quantify specific cDNAs using
the Bio-Rad SYBR Green intercalating fluorophore system with
a Bio-Rad I-cycler thermocycler and fluorescence detector (Bio-
Rad, Hercules, CA, USA). Primers for genes highly induced by type
I IFN signaling-interferon induced with tetratricopeptide repeats
1 (IFIT-1, Forward CTCCTTGGGTTCGTCTATAAATTG; Reverse
AGTCAGCAGCCAGTCTCAG), Protein kinase R (PKR) (Forward
CTTCCATCTGACTCAGGTTT; Reverse TGCTTCTGACGGTAT-
GTATTA), interferon-induced protein with tetratricopeptide
repeats 3 (IFIT-3, Forward GGCAGACAGGAAGACTTCTGAA-
GAACA; Reverse TGACTGCCCTCT-GTGTCTCTGCT), myx-
ovirus (influenza virus) resistance 1 (MX-1, Forward TACCAGG
ACTACGAGATTG-Reverse TGCCAGGAAGGTCTATTAG) were
used in the PCR reaction on the WISH cell derived cDNAs.
The housekeeping gene Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH, Forward CAACGGATTTGGTCGTATT; Reverse
GATGGCAACAA-TATCCACTT) was also quantified in the cDNA
samples to control for background gene expression. The type I
IFN-induced genes are compared with housekeeping gene expres-
sion to determine relative expression. The relative expression is
then normalized to the relative expression of the respective genes
in unstimulated cells from the same population. Type I IFN activity
was calculated as the average relative expression of IFN-inducible
genes (IFIT-1 and PKR in the thyroid cohort and IFIT-3, PKR,
MX-1 in the diabetes cohort). The cut-off for high serum type I
IFN activity among patient samples was defined as the mean plus
1 SD of the IFN activity score of sera from healthy donors (HD)
(cut-off for high activity= 1.29, for ATD patients and 0.87 for
T1DM patients).
IFIH1 GENOTYPING
The rs1990760 SNP in IFIH1 was genotyped in ATD patients using
real-time PCR with Applied Biosystems Assays-by-Design Taqman
primer and allele specific fluorescent labeled probes. Reactions
were run using 10 ng of genomic DNA along with primers and
probes on an ABI 7900HT PCR machine per manufacturer proto-
col. Genotype calls were made from clustering diagrams at>99%
certainty, and the call rate was >90%.
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AUTOANTIBODY ASSAYS
Anti-Ro/SSA and anti-RNP/Sm antibodies in the ATD patients
were determined by commercial ELISA (Diamedix, FL, USA).
Anti-Tg and anti-TPO autoantibodies were measured in the same
laboratory using a two-site immunoluminometric assay (Dia-
Sorin, LIASON analyzer, normal range: <100 and <25 IU/mL
respectively). TRAbs were measured using commercial kit (Dia-
Sorin Inc., Stillwater, MN, USA, cut-off value: 10%).
THYROID ULTRASONOGRAPHY
Thyroid ultrasonography was carried out in 17 ATD patients using
a high-resolution apparatus (Logic-Book XP, General Electric Co.,
USA) equipped with a 6–11 MHz broadband linear array probe by
a single operator who was unaware of the diagnosis.
High-sensitivity color flow Doppler sonography was used to
estimate the intraparenchymal blood flow pattern. The vascular-
ity index and the hypoechogenicity index were calculated for all
images as previously described (21). Thyroid volume was mea-
sured and the presence of nodules was also recorded [micronod-
ules (diameter<10 mm) and macronodules (diameter>10 mm)].
In addition, thyroid blood flow was also measured at the inferior
thyroid artery (16).
STATISTICAL ANALYSIS
Two-group comparisons of continuous data were assessed using
unpaired t -test on non-parametric Mann–Whitney test for nor-
mally or not normally distributed data respectively. Fisher’s exact
two-tailed test was used for categorical variables. Correlations
between quantitative variables were performed by Spearman’s rho
test. Our multivariate analysis consisted of a stepwise logistic
regression that was used to identify independent variables that
could be associated with high or low type I IFN serum activity in
ATD patients. The variables entered in the multivariate model were
those shown to be statistically significantly different between high
and low IFN groups based on the bivariate analysis (p< 0.05).
RESULTS
ATD COHORT
Type I IFN activity in ATD patients and controls
In order to explore whether activation of the type I IFN pathway
occurs in the context of ATD, type I IFN serum activity was deter-
mined by a reporter cell assay (please see Patients and Methods for
details) in 39 ATD patients (26 with HT, 12 with GD) and 39 HC of
similar age, sex, and race distribution (Table 1). Patients with ATD
had increased type I IFN activity compared to HC (mean± SD:
1.2± 0.4 vs. 0.9± 0.4, p= 0.002) (Figure 1A). Following these
findings patients with ATD were subdivided further according to
type I IFN activity into those with “high” (13 patients) and “low”
(26 patients) IFN score.
Clinical and serological correlates of type I IFN activity among ATD
patients
In order to determine whether high serum type I IFN activity
is associated with the presence of any clinical and serological
parameters, we compared the “high” and “low”-IFN score ATD
patients using bivariate analysis. Comparisons between the two
groups were performed for demographic variables, systemic man-
ifestations, thyroid function, and antibodies. As shown in Table 2,
Table 1 | Demographic characteristics of the study subjects.
ATD patients
(n=39)
Healthy
controls
(n=39)
p-Value
No. of subjects 39 39
Mean age±SD (years) 48.9±14.4 47.6±11.2 ns
Female to male ratio 4.6:1 4.6:1 ns
Mean disease duration±SD (years) 5±5.2 NA NA
% Caucasians 100 100 1
No of patients with GD 12 NA NA
No of patients with Hashitoxicosis 1 NA NA
No of patients with HT 26 NA NA
GD, Grave’s disease; HT, Hashimoto’s disease; ATD, autoimmune thyroid disease;
SD, Standard Deviation; NA, not applicable; ns, no significant.
anti-Tg antibodies were present in almost all patients of the “high”
IFN group, compared to less than 50% of the “low” IFN patients
(p= 0.013).
Cardiopulmonary manifestations were significantly more fre-
quent in the “high”-IFN ATD group (46 vs. 8%, p= 0.011) and
included shortness of breath on exertion in two individuals
(possibly related to heart failure), pericarditis in one individ-
ual, asthma in two cases, and interstitial lung disease in another
one. In the low IFN group two cases of asthma were reported.
Autoantibodies against Ro/SSA and RNP/Sm nucleoproteins, pre-
viously shown to be associated with high type I IFN activity in
SLE patients (22), were negative in all ATD subjects (data not
shown). No correlations were found between type I IFN levels
and autoantibodies to TSHR (r =−0.163, p= 0.396) by Spear-
man’s correlation test. Logistic regression analysis revealed an
independent association of high IFN-α activity with the presence
of anti-Tg antibodies (OR= 17.69, 95% CI: 2.05–560.9) and car-
diopulmonary manifestations (OR= 15.34, 95% CI: 1.95–335.5)
respectively.
Type I IFN activity and thyroid ultrasonographic pattern
We next sought to explore whether type I IFN activity serum
levels were associated with ultrasonographic parameters of the
thyroid gland. While no significant associations were detected
between type I IFN levels and the various ultrasonographic
indices examined including thyroid volume, vascularity and
hypogenicity indexes, macronodules and inferior thyroid artery
blood flow (data not shown), higher type I IFN activity was
found in patients with ATD and thyroid micronodules (p= 0.04)
(Figure 1B).
IFIH1 genotypes and IFN levels in ATD patients
To determine whether the IFIH1 risk variant is associated with
higher type I IFN levels, the rs1990760 SNP in IFIH1 was geno-
typed. No association was found between genotypes and type
I IFN levels (data not shown). However, a trend toward higher
prevalence of the T risk allele among patients with low TSH levels
compared to those with high TSH levels (77.7 vs. 50%, OR= 3.5,
CI: 0.9–13.3, p= 0.07) was found, consistent with the previously
reported association of the T allele of the IFIH1 with GD (10).
www.frontiersin.org August 2013 | Volume 4 | Article 238 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mavragani et al. Type I interferon and organ-specific autoimmunity
          p=0.002
A
TD
 (n
=3
9)
H
D
 (n
=3
9)
0.0
0.5
1.0
1.5
2.0
2.5
A
T
yp
e
 I
 I
F
N
 a
ct
iv
it
y
  p=0.01
M
ic
ro
no
du
le
s(
-)(
n=
7)
M
ic
ro
no
du
le
s(
+)
(n
=8
)
0.0
0.5
1.0
1.5
2.0
B
T
yp
e
 I
 I
F
N
 a
ct
iv
it
y
FIGURE 1 | (A) Increased type I interferon (IFN) activity in patients with
autoimmune thyroid disease (ATD) compared to healthy donors (HD). Serum
type I IFN activity was assessed using a sensitive reporter cell assay in 39
patients with autoimmune thyroid disease (ATD) and 39 age-sex matched
healthy controls (HC). Results are expressed as an IFN score, as described in
materials and methods. Symbols represent individual subjects; horizontal
lines represent the mean; p-values were calculated by unpaired t -test. (B)
Significantly higher serum type I IFN activity levels in ATD patients with
ultrasonographic presence of thyroid micronodules. Serum type I IFN activity
assessed using a sensitive reporter cell assay was found to be higher in ATD
patients characterized by the presence of micronodules on ultrasound (n=8)
compared to those without such nodules (n=7). Data are shown as box
plots. Each box represents the 25–75th percentiles. Lines inside the box
represent the median. Lines outside the box represent the 10th and the 90th
percentiles; p-values were calculated by unpaired t -test. Micronodules (+):
presence of micronodules, micronodules (−): absence of micronodules.
T1DM COHORT
Type I IFN activity in T1DM patients and controls-clinical and
laboratory correlates
In order to investigate whether type I IFN pathway is activated in
the setting of T1DM, serum type I IFN activity was determined
in 88 pediatric T1DM patients and 46 controls of similar age,
sex, and body mass index (BMI) distribution (Table 3) by the
previously described reporter cell assay. As shown in Figure 2,
type I IFN activity was found to be significantly increased in
pediatric patients with T1DM compared to age-sex matched con-
trols (mean± SD:1.1± 2.2 vs. 0.6± 0.3, p= 0.04). Of interest,
apolipoprotein-B levels were higher in T1DM patients with high
type I IFN activity. No other associations with clinical and/or
serological data were observed (Table 4).
DISCUSSION
While several lines of evidence suggest a central role for the
type I IFN pathway in the pathogenesis of a number of systemic
autoimmune disorders, more limited data are available regarding
its contribution to the pathogenesis of organ-specific autoim-
mune disease and its potential association with distinct clinical
or serological phenotypes. The current study provides evidence
of elevated serum type I IFN activity in approximately one third
of patients with ATD and one fifth of those with T1DM, using a
functional IFN assay.
Designation of ATD and T1DM patients as patients with “high”
or “low” type I IFN activity allowed us to test the hypothesis
that type I IFN pathway activation identifies ATD and T1DM
patients with distinct clinical and serological characteristics. Fol-
lowing both bivariate and multivariate analysis, the presence of
anti-TG, but not anti-TPO was associated with a high IFN sta-
tus among ATD patients. Of interest, a recent study identified
SNP (_1623A/G) of the TG gene – previously identified as a
major ATD susceptible variant – to modify a binding site for the
IFN-induced transcription factor interferon regulatory factor-1
(IRF-1), leading to increased promoter activity and increased TG
levels, a major antigenic target for ATD (23). However, the presence
of such genetic variant was not assessed in our patient popula-
tion. Additionally, stimulation of rat thyroidal cells with IFN-α has
been shown to lead to persistent (up to 48 h) increase of TG lev-
els through TG promoter activation suggesting that IFN-induced
upregulation of the TG autoantigen could lead to generation of
antigen specific serum reactivities. Though upregulation of TPO
was also observed, this was limited to 24 h and seemed to be
independent from the activation of the TPO promoter (24). As
no antibodies against Ro/SSA and RNP/Sm antigens were found,
those antibodies cannot be implicated in the induction of type I
IFN, as has been proposed for SLE (22).
Interestingly, high IFN status was also associated with increased
prevalence of cardiopulmonary features. Although IFN-αhas been
previously linked to atherosclerotic risk and a negative effect of
IFN-α on vascular endothelial cells has been demonstrated (25,
26), the pathophysiological implication of this association in ATD
will require further investigation. ATD patients with increased type
I IFN levels exhibited mostly micronodular sonographic appear-
ance which is related to the presence of lymphocytic aggregates
with germinal centers and/or transformed follicular oxyphilic cells
(27). Given that type I IFN has been previously associated with
B-cell activation and immunoglobulin class switching (28), the
relation of micronodulation to type I IFN activity could reflect the
contribution of the latter in the pathophysiology of ATD disease.
Whilst no significant associations were detected between levels of
type I IFN activity and genotypes of the IFIH1 gene, a trend toward
increased prevalence of the T risk allele among patients with low
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Table 2 | Comparison of ATD patients with low or high type I IFN
activity in bivariate analysis.
Variable Type I IFN activity
Low
(n=26)
High
(n=13)
p
Mean type I IFN activity score 0.98±0.19 1.6±0.23 <0.0001
DEMOGRAPHICS
Age, years 47.08±15.16 52.91±12.33 0.278
Disease duration, years 4.32±4.78 6.54±6.03 0.318
No of females 22/26 (84.6%) 10/13 (76.9%) 0.666
SYSTEMIC MANIFESTATIONS
Skin manifestations 8/25 (32%) 7/13 (53.8%) 0.295
Musculoskeletal manifestations 7/25 (28%) 6/13 (46.1%) 0.30
Oral ulcers 6/25 (24%) 0/11 (0%) 0.147
Raynaud’s phenomenon 4/25 (16%) 1/13 (7%) 0.642
Sicca symptoms 5/25 (20%) 3/13 (23.1%) 1
Cardiopulmonary 2/25 (8%) 6/13 (46.1%) 0.011
Renal 0/25 (0%) 0/12 (0%) 1
Hematological 0/24 (0%) 0/11 (0%) 1
Neurologic
Headaches 13/25 (52%) 2/13 (15.3%) 0.039
Other* 2/25 (8%) 1/13 (7.7%) 1
ABS AGAINSTTHYROID ANTIGENS
Positive anti-Tg autoAbs 12/25 (48%) 11/12 (91.6%) 0.013
Positive anti-TPO autoAbs 21/25 (84%) 11/12 (91.6%) 1
TYPE OFTHYROID DISORDER
Graves’ disease 8/26 (30.7%) 4/13 (30.7%) 1
Hashimoto’s/Hashitoxicosis 18/26 (69.3%) 9/13 (69.3%) 1
THYROID FUNCTIONTESTS
High TSH 12/26 (46.1%) 8/13 (61.5%) 0.5
Low TSH 9/26 (34.6.9%) 4/13 (30.7%) 1
Other* (includes stroke, white matter microangiopathy, transverse myelitis,
cranial/peripheral neuropathy).
Table 3 | Characteristics of theT1DM patients and healthy subjects.
Healthy
subjects
(n=46)
T1DM
patients
(n=88)
p
Age (years) 10.53±0.64 12.12±0.57 ns
Female to male ratio 0.8:1 1.1:1 ns
Body mass index (kg/m2) 21.16±0.20 20.79±0.58 ns
Diabetes duration (months) – 57.82±7.83 (0–184) NA
ns, no significant; NA, not applicable.
TSH levels (defined as <0.5 IU/mL) compared to those with high
TSH levels was noted. This finding is consistent with the previ-
ously reported association of the T risk allele of the IFIH1 with
GD (10).
The association between type I IFN and thyroid disease was
first appreciated in 1985 in patients treated with IFN-α for breast
cancer (29). Since then, a large number of studies have revealed a
high incidence of thyroid abnormalities in IFN-α treated patients,
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FIGURE 2 | Increased type I IFN activity in patients with type 1
diabetes mellitus (T1DM) (n=88) compared to healthy donors (HD)
(n=46). Serum type I IFN activity was assessed using a sensitive reporter
cell assay as previously described. Symbols represent individual subjects;
horizontal lines represent the mean; p-values were calculated by
non-parametric Mann–Whitney test.
Table 4 | Comparison ofTIDM patients with low or high type I IFN
activity in bivariate analysis.
Variable Type I IFN activity
Low
(n=72)
High
(n=16)
p
Mean type I IFN activity score 0.57±0.15 3.06±4.86 <0.0001
Age (years) 11.96±0.74 13.00±1.03 0.500
Female to male ratio 1.2 1.3 1
Body mass index (kg/m2) 20.90±0.67 20.21±1.43 0.640
Diabetes duration (months) 59.19±9.25 48.45±17.26 0.583
Total cholesterol (mg/dL) 165.51±5.31 167.27±7.61 0.869
HDL (mg/dL) 59.16±1.74 59.55±2.94 0.915
LDL (mg/dL) 91.95±4.06 90.00±5.48 0.810
Total triglycerides (mg/dL) 70.51±6.31 73.00±10.03 0.847
Lipoprotein (a) (mg/dL) 12.86±1.84 13.50±3.62 0.873
Apolipoprotein-A (mg/dL) 126.46±4.85 137.57±10.70 0.305
Apolipoprotein-B (mg/dL) 81.63±4.16 91.43±1.62 0.037
Urine microalbumin (mg/L) 7.33±0.99 6.83±1.73 0.813
Serum creatinine (mg/dL) 0.64±0.021 0.65±0.06 0.977
Serum urea (mg/dL) 29.59±1.08 31.73±4.94 0.681
CRP (mg/dL) 5.00±1.21 5.91±3.03 0.744
HbA1c (%) 8.08±0.27 7.77±0.42 0.599
ranging from development of thyroid autoantibodies to overt ATD
such as GD or HD (30). IFN-α treatment has been shown to exac-
erbate preexisting thyroid autoimmunity by increasing the titers
of antithyroid antibodies (31). Although unclear, the potential
mechanisms through which IFN-α might promote the develop-
ment of thyroid autoimmunity are multiple, including facilitation
of antigen presentation through increased expression of the adhe-
sion and costimulatory molecules ICAM-1, B7.1, and MHC class I
antigens on thyrocytes, activation of cytotoxic T-cells, promotion
of autoantibody production through direct and indirect effects
on B-cell and immunoglobulin class switching, upregulation of
thyroid specific antigens, and direct toxicity on thyroidal cells
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(18, 24). Recently, functional sensors detecting both exogenous
and endogenous signals were detected in thyroid cells promot-
ing induction of innate immune responses including activation
of type I IFN pathway. In particular, stimulation of thyroid cells
with Toll-like receptor ligands led to activation of the interferon-
beta (IFN-β) promoter (32). Though therapeutic administration
of IFN-α in patients with HCV infection has been mainly asso-
ciated with induction of ATD, several reports derived from the
multiple sclerosis (MS) literature suggest IFN-β as an inducer of
ATD among MS patients possibly through stimulation of CXCL10
secretion by thyrocytes (33, 34). Unfortunately, in the present
study, exploring whether type I IFN activity was mainly related
to IFN-α or IFN-β components was not included in the initial
design of the study.
Recent findings have revealed an upregulation of IFN-α
inducible genes in peripheral blood mononuclear cells in patients
with GD, which correlated with TSHR messenger RNA and pro-
tein levels of HLA-DR and IFN-α (35). Although stimulation
of primary cultured thyrocytes with recombinant human IFN-α
resulted in increased expression of MHC-II antigens and TSHR
in these patients, no serum IFN type I activity was detected
in the samples tested. IFN-α levels – measured by a commer-
cially available enzyme immunoassay – were also found to be
increased in a small cohort of patients with several thyroid dis-
orders including 12 Grave’s disease and four patients with HT.
No associations with distinct clinical, serological, or imaging find-
ings were reported (36). Finally, data from a recent report revealed
heightened levels of the type I IFN-inducible myxovirus resistance
protein A in thyroid tissue derived from early HT patients fur-
ther reinforcing the implication of the type I IFN pathway in ATD
pathogenesis (37).
Activation of the type I IFN pathway was also confirmed in
our pediatric diabetic cohort – the largest so far tested, with
approximately 20% of patients demonstrating raised serum type
I IFN levels, by a sensitive bioassay. The contribution of type
I IFN in the pathogenesis of autoimmune T1DM has been
previously postulated in both human and animal studies (38–
40). Earlier data from a relatively small cohort of mixed adult
and pediatric populations demonstrated raised IFN-α in periph-
eral blood at the mRNA and protein level which correlated
well with blood enteroviral RNA, implying a role of enterovi-
ral infection in the pathogenesis of T1DM (39). No clinical
or serological associations of type I IFN pathway with disease
related biomarkers were reported in that study. On the other
hand, endogenous nucleic acids derived from apoptotic pancre-
atic β cells were also proposed as potential triggers of IFN-α
production by plasmacytoid dendritic cells, leading to activation
of autoreactive CD4+ T-cells which ultimately lead to destruction
of insulin producing pancreatic islets (41). Of interest, in a
recently reported animal model of virus induced T1DM, defec-
tive function of viral sensors with impaired type I responses was
associated with development of the disease and was related to
defective clearance of a virus directed against the beta cells of the
pancreas (42).
In the current study, apolipoprotein-B levels – previously
shown to be associated with pronounced atherosclerotic risk (43,
44) – were increased in the high IFN group in our T1DM cohort.
Of interest, apolipoprotein-B is a member of the APOBEC fam-
ily of proteins, many of which are regulated by type I interferons
and particularly IFN-α (45, 46). Whilst it is not known whether
increased apolipoprotein-B levels are directly induced by type I
IFN, such a probability remains, providing an additional mecha-
nism by which type I IFN might contribute to the pathogenesis of
atherosclerosis (47).
The demonstration of type I IFN activity in serum of patients
with ATD and T1DM, supports its role in the pathogenesis of both
organ-specific and systemic autoimmune disorders. While the rea-
sons for the tissue specificity in the autoimmune process remain
elusive, the identification of the type I IFN pathway as a common
pathogenetic denominator among distinct and diverse autoim-
mune phenotypes may explain the similarities found in patients
with IFN-related disorders, such as strong familial aggregation
and female predominance, and contribute to the identification
of unifying underlying determinants of autoimmunity. Familial
aggregation of both high IFN and ATD in SLE families could
support a case for IFN being causal in both (48).
In conclusion, the findings of the present study support a role
for type I IFN in the pathogenesis of organ-specific autoimmune
disorders, particularly in ATD and T1DM patients. These data
extend our current list of type I IFN-related autoimmune disor-
ders and may provide insight into shared pathogenic factors and
suggest new targets for therapeutic intervention.
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